We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Gene Technology Outperforms Standard Newborn Screening Tests in Pioneering Study

By LabMedica International staff writers
Posted on 05 Nov 2024
Print article
Image: Genome sequencing technology has the potential to detect thousands of genetic disease (Photo courtesy of 123RF)
Image: Genome sequencing technology has the potential to detect thousands of genetic disease (Photo courtesy of 123RF)

Since its introduction in the 1960s, newborn screening has grown to encompass dozens of primarily genetic disorders. The standard approach to newborn screening involves detecting specific biomarkers in blood that are associated with various conditions. However, many diseases still lack identifiable blood biomarkers, which limits the effectiveness of current screening methods. In contrast, genome sequencing, which was once rare and prohibitively expensive, has become increasingly accessible and affordable for clinical use, making it a potentially superior option for newborn screening. This technique analyzes a newborn’s DNA to identify hundreds of specific gene variants known to cause diseases, with the capability to detect thousands of genetic disorders—far exceeding the approximately 60 conditions currently identified through standard newborn screening. The genes included in newborn screening can lead to diseases that, if diagnosed early in infancy, could be prevented or treated. Now, early results from a study on newborn screening methods indicate that DNA analysis identifies significantly more preventable or treatable serious health conditions compared to standard newborn screening and is preferred by most parents offered this option.

The GUARDIAN study, conducted by researchers at Columbia University Irving Medical Center (New York, NY, USA), is one of the first large-scale studies globally to utilize genome sequencing for newborn screening and is the first to publish preliminary findings. Launched in September 2022, the GUARDIAN study provided genome sequencing to every newborn at NewYork-Presbyterian hospitals in New York City. In its inaugural year, GUARDIAN assessed genes associated with 156 rare but treatable conditions. Parents had the option to include an additional panel of 99 conditions that currently lack treatments but may benefit from early intervention. The study utilized DNA from the same dried blood spots collected at birth for traditional newborn screening, which is processed for each participant by the New York State Department of Health’s Newborn Screening Program.

Out of 147 children who screened positive using genome sequencing, 120 were confirmed true positives and diagnosed with a rare condition, with only 10 identified through standard screening methods. Most of the children diagnosed with a genetic condition (92 out of 120) had glucose-6-phosphate dehydrogenase deficiency (G6PD), an enzyme deficiency not included in traditional screening. Individuals with G6PD deficiency can experience moderate to life-threatening reactions to specific foods and medications, which can be easily prevented by avoiding those triggers. In one instance, genome sequencing identified a critical condition—severe combined immunodeficiency disorder (SCID), often referred to as “bubble boy syndrome”—that was missed by standard screening. The presence of a rare genetic variant causing SCID was detected, allowing doctors to protect the infant from life-threatening infections before they could occur.

Overall, 3.7% of children in the study tested positive for a genetic condition. Excluding G6PD cases, the positive screening rate was 0.6%, which is double the 0.3% rate achieved through standard screening in New York state. Parental acceptance of genome sequencing for newborn screening was notably high, with 72% of families approached agreeing to participate, and 90% of participants opting for the additional screening for untreatable conditions. The GUARDIAN study is now investigating gene variants linked to more than 450 conditions, with dozens of new conditions being identified each year. The ongoing study aims to enroll 100,000 infants in the coming years to gain insights into parental perceptions regarding genome sequencing, the associated costs, privacy concerns, and challenges in interpreting results across diverse ancestral backgrounds.

“The results show us that genome sequencing can radically improve children’s medical care,” said Joshua Milner, professor of Pediatrics, director of Allergy/Immunology and Rheumatology at Columbia University Vagelos College of Physicians and Surgeons, and one of the study’s co-authors. “Genome sequencing allows us to detect things that cause serious illness and take action to prevent those illnesses in a significant number of children, not just a few rare cases. It should be instituted as the next standard for newborn screening because it can detect so much more than current methods.”

Related Links:
Columbia University Irving Medical Center

Gold Member
Hematology Analyzer
Swelab Lumi
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
PSA Test
Human Semen Rapid Test
New
Histamine ELISA
Histamine ELISA

Print article

Channels

Hematology

view channel
Image: Personalized blood count could lead to early intervention for common diseases (Photo courtesy of 123RF)

Personalized CBC Testing Could Help Diagnose Early-Stage Diseases in Healthy Individuals

A complete blood count (CBC) screening is a standard examination most physicians request for healthy adults. This test is essential for evaluating a patient’s overall health with a single blood sample.... Read more

Immunology

view channel
Image: Concept for the device. Memory B cells able to bind influenza virus remain stuck to channels despite shear forces (Photo courtesy of Steven George/UC Davis)

Microfluidic Chip-Based Device to Measure Viral Immunity

Each winter, a new variant of influenza emerges, posing a challenge for immunity. People who have previously been infected or vaccinated against the flu may have some level of protection, but how well... Read more

Microbiology

view channel
Image: The BIOFIRE® FILMARRAY® Tropical Fever Panel has received U.S. FDA Special 510(k) clearance (Photo courtesy of bioMérieux)

Syndromic PCR Test Rapidly and Accurately Identifies Pathogens in Patients with Tropical Fever Infections

Tropical fevers refer to infections that are common in, or unique to, tropical and subtropical regions. As these diseases spread to previously unaffected areas and can be brought in by travelers, infections... Read more

Pathology

view channel
Image: The new study highlights efficiency in detecting infectious diseases (Photo courtesy of Adobe Stock)

Optimized Pooled Testing Approach Could Transform Public Health Screening for Infectious Diseases

Traditional individual testing methods can be resource-intensive, particularly when it comes to large-scale screenings. Pooled testing, on the other hand, enables the testing of multiple specimens together,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.